The Contribution of DNA Methyltransferase Inhibitors in Treating Myelodysplastic Syndromes
Tuesday, 01 October 2019
Myelodysplastic syndromes (MDS) are a broad, complex group of cancers characterized by the inability to form mature, healthy blood cells. There are different types with varying degrees of risk associated, making it difficult to diagnose and treat. Additionally, many patients are symptom-free and at an older age where they are likely to have other life-threatening
- Published in Emerging Targets, Epigenetics
No Comments